The Oncology Institute, Inc. (NASDAQ:TOI – Get Rating) COO Matthew P. Miller acquired 73,684 shares of the stock in a transaction dated Friday, December 16th. The shares were bought at an average price of $0.95 per share, for a total transaction of $69,999.80. Following the transaction, the chief operating officer now owns 175,325 shares in the company, valued at approximately $166,558.75. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link.
Oncology Institute Price Performance
Shares of NASDAQ:TOI opened at $0.97 on Wednesday. The stock has a market cap of $69.88 million, a PE ratio of -5.68 and a beta of 1.32. The company's fifty day moving average is $2.77 and its 200 day moving average is $4.78. The Oncology Institute, Inc. has a 52 week low of $0.86 and a 52 week high of $12.66. The company has a quick ratio of 4.07, a current ratio of 4.37 and a debt-to-equity ratio of 0.62.
Get Oncology Institute alerts:Wall Street Analyst Weigh In
Separately, Guggenheim lowered their price objective on shares of Oncology Institute from $7.00 to $6.00 and set a "buy" rating on the stock in a research report on Friday, November 11th.
Hedge Funds Weigh In On Oncology Institute
A number of large investors have recently added to or reduced their stakes in the business. Deerfield Management Company L.P. Series C raised its position in Oncology Institute by 2.6% in the 2nd quarter. Deerfield Management Company L.P. Series C now owns 3,383,099 shares of the company's stock worth $17,118,000 after purchasing an additional 86,992 shares during the period. Vanguard Group Inc. raised its position in Oncology Institute by 18.1% in the 3rd quarter. Vanguard Group Inc. now owns 1,860,242 shares of the company's stock worth $8,613,000 after purchasing an additional 284,807 shares during the period. BlackRock Inc. raised its position in Oncology Institute by 101.8% in the 3rd quarter. BlackRock Inc. now owns 1,529,650 shares of the company's stock worth $7,083,000 after purchasing an additional 771,555 shares during the period. Triatomic Management LP raised its position in Oncology Institute by 7.0% in the 1st quarter. Triatomic Management LP now owns 428,100 shares of the company's stock worth $3,052,000 after purchasing an additional 28,100 shares during the period. Finally, State Street Corp raised its position in Oncology Institute by 45.1% in the 3rd quarter. State Street Corp now owns 288,127 shares of the company's stock worth $1,334,000 after purchasing an additional 89,500 shares during the period. Hedge funds and other institutional investors own 69.97% of the company's stock.About Oncology Institute
(Get Rating)
The Oncology Institute, Inc, an oncology company, provides medical oncology services in the United States. Its services include physician services, in-house infusion and dispensary, clinical trial services, radiation, outpatient stem cell transplants and transfusions programs, and patient support. The company also offers and manages clinical trial services, such as managing clinical trials, palliative care programs, and stem cell transplants services.
Further Reading
- Get a free copy of the StockNews.com research report on Oncology Institute (TOI)
- Will AMC's Troubles Affect Its Landlord, EPR Properties?
- Is There a Prize in Store for Kellogg Shareholders?
- General Mills Retreats To More Attractive Territory
- Will Tesla Shares Rally If Musk Steps Down From Twitter?
- Can Chewy Fetch Double Digit Gains in 2023?
Receive News & Ratings for Oncology Institute Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncology Institute and related companies with MarketBeat.com's FREE daily email newsletter.